Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio) confirmed that shareholders approved the election of Chen Liang as an Independent Non-Executive Director at the annual general meeting on 26 June 2026. The appointment took effect immediately and will run through the end of the company’s fourth Board session, subject to the standard rotation and re-appointment mechanism.
Under the service contract, Chen Liang will receive a director’s fee of RMB0.20 million per year. He has declared compliance with all independence criteria under Rule 3.13 of the Hong Kong Listing Rules and reported no financial or other ties with the Group or its core connected persons.
Board-level committee structures were also updated, effective 26 June 2026:
• Audit Committee – Li Zhongxian becomes chairman, joined by members Chen Liang and non-executive director Tang Yi. • Remuneration and Appraisal Committee – Li Zhongxian assumes the chair, alongside independent directors Yang Jin and Feng Xiaoyuan, and executive directors Xiong Jun and Zou Jianjun. • Strategic and ESG Committee – chaired by executive director Xiong Jun, with executive directors Zou Jianjun and Wang Gang, and independent directors Feng Xiaoyuan and Li Zhongxian. • Compliance Committee – chaired by independent director Lu Kun, with members Li Zhongxian and Chen Liang.
The Board expressed appreciation for the new appointments, noting that the adjustments complete the committee lineup for the current Board term announced on 26 June 2026.
Comments